Shuttle Pharmaceuticals Holdings, Inc. (SHPH) NASDAQ
0.53
-0.0076(-1.43%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.53
-0.0076(-1.43%)
Currency In USD
Address
One Research Court
Gaithersburg, MD 20850
United States of America (the)
Phone
240 403 4212
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9
First IPO Date
August 31, 2022
| Name | Title | Pay | Year Born |
| Christopher Robert Cooper | Interim CEO & Director | 240,001 | 1970 |
| Milton Brown | Co-Founder | 4,167 | 1965 |
| Yuying Liang | Chief Financial Officer | 177,511 | 1991 |
| Tyvin A. Rich | Chief Clinical Officer & Chief Medical Officer | 218,000 | 1948 |
| Michael Vander Hoek | Vice President for Operations and Regulatory | 506,634 | 1960 |
| Mira Jung | Co-Founder & Chief Scientific Officer for Biology | 0 | 1949 |
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.